1-(4-氨基-2-羟基苯基)-1-丙酮 | 83294-23-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(4-氨基-2-羟基苯基)-1-丙酮
• 英文名称: 1-(4-amino-2-hydroxy-phenyl)-propan-1-one
• 英文别名: 1-(4-Amino-2-hydroxy-phenyl)-propan-1-on；1-(4-Amino-2-hydroxyphenyl)propan-1-one
• CAS: 83294-23-9
• 化学式: C₉H₁₁NO₂
• mdl: MFCD00218584
• 分子量: 165.192
• InChiKey: GTOIQUKRGYQXBK-UHFFFAOYSA-N

物化性质

• 熔点：
  137°C
• 沸点：
  340.0±22.0 °C(Predicted)
• 密度：
  1.195±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922509090

反应信息

• 作为产物：
  描述：

  3’-甲氧基乙酰苯胺 在 盐酸 、 三氯化铝 、 1,2-二氯乙烷 作用下， 生成 1-(4-氨基-2-羟基苯基)-1-丙酮
  参考文献：
  名称：

  Julia; Baillarge, Bulletin de la Societe Chimique de France, 1952, p. 639

  摘要：

  DOI：

文献信息

• Compositions and methods for the treatment of irritable bowel syndrome
  申请人：CELLIX BIO PRIVATE LIMITED

  公开号：US11078154B2

  公开（公告）日：2021-08-03

  The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

  本文公开的化合物为式 I 或其药用盐，以及它们的多晶型物、对映体、立体异构体、溶解物和水合物。这些盐类可配制成药物组合物。这些药物组合物可配制成口服、栓剂、透皮、口腔、直肠、局部、透皮、透粘膜、静脉注射、肠外给药、糖浆或注射剂。此类组合物可用于治疗肠易激综合征（IBS）、炎症性肠病或其相关并发症。
• Compositions and methods for the treatment of gastrointestinal polyps
  申请人：CELLIX BIO PRIVATE LIMITED

  公开号：US11225464B2

  公开（公告）日：2022-01-18

  The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V and formula VI or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications.

  本文公开了式 I、式 II、式 III、式 IV、式 V 和式 VI 的化合物或其药物可接受盐，以及它们的多晶型物、对映体、立体异构体、溶液和水合物。这些盐类可配制成药物组合物。这些药物组合物可配制成口服、口腔、直肠、局部、透皮、透粘膜、锭剂、喷雾剂、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。此类组合物可用于治疗胃肠道息肉或其相关并发症。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
  申请人：Cellixbio Private Limited

  公开号：EP2852569B1

  公开（公告）日：2020-10-14
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME
  申请人：CELLIX BIO PRIVATE LIMITED

  公开号：US20190177267A1

  公开（公告）日：2019-06-13

  The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS
  申请人：CELLIX BIO PRIVATE LIMITED

  公开号：US20200190040A1

  公开（公告）日：2020-06-18

  The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V and formula VI or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications.